# Amgen: Phase 1 study started recruiting, 308 planned (Healthy Participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Amgen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections |
| NCT ID | NCT07811999 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Healthy Participants |
| Intervention types | drug |
| Target enrollment | 308 |
| Site countries | United States, United Kingdom |
| Posted | 2026-09-10 |
| Planned start | 2026-09-22 |
| Event | Started recruiting |
| Event date | 2026-09-22 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- 308 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07811999). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.